What Half-Life Actually Measures
A peptide's half-life is the time it takes for blood concentrations to fall by half after administration. A compound with a two-hour half-life is mostly cleared by bedtime. A compound with a seven-day half-life keeps a fairly steady background level all week. Dosing schedules follow directly from that number.
The confusion in peptide research discussions usually comes from comparing compounds with wildly different half-lives as if they followed the same rules. They don't.
The Short End: Minutes to Hours
Most research peptides fall here.
Growth hormone secretagogues: Ipamorelin's half-life is roughly two hours, and the GHRH analogs are measured in minutes. That is why secretagogue protocols in the research literature use daily dosing, sometimes split into two or three administrations spaced across the day. The compound does its signaling work and is gone.
BPC-157: Animal pharmacokinetic work shows rapid clearance, which matches how the compound is used in animal studies: frequent administration over a defined period rather than spaced-out doses.
PT-141 and other short-acting peptides: Onset within hours and clearance within a day shapes how researchers schedule them around an observed effect window rather than a calendar.
With short-lived compounds, the research convention is frequency. The compound needs to be present when the biological process you are studying is running.
The Long End: Days to Weeks
The other extreme comes from deliberate chemical engineering.
Semaglutide carries a half-life of about one week, achieved by attaching a fatty acid side chain that lets the molecule bind albumin and resist enzymatic breakdown. One administration per week is enough to keep therapeutic-range concentrations.
Tirzepatide (roughly five days) and retatrutide (roughly six days) use the same strategy. Weekly dosing is a design feature of these molecules, not a convenience choice.
CJC-1295 with DAC applies a similar trick to a GHRH analog. Drug affinity complex binding to albumin stretches the half-life from minutes to around six to eight days, which is why the with-DAC and without-DAC versions of this compound have completely different schedules.
What This Means for Reading Protocols
When you look at a research protocol, the dosing frequency is usually the half-life talking:
Comparing a 5 mg weekly vial against a 5 mg daily vial tells you very little on its own. The concentration at any moment, and how long it stays there, is what separates these schedules.
Caveats Worth Knowing
Animal half-lives do not always translate cleanly to humans, and published pharmacokinetic data for many research compounds is thin or absent. Where a half-life is not well established in the literature, protocols tend to inherit their schedules from animal studies or from convention. Treat any schedule built on shaky pharmacokinetics as a hypothesis being tested, and not settled practice.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice.